Broad efficacy and improved safety profile of hybryte™ presented at society for investigative dermatology virtual meeting

Princeton, n.j., may 4, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that ellen kim, md, medical director, dermatology clinic, perelman center for advanced medicine, professor of dermatology at the hospital of the university of pennsylvania, and the lead principal investigator for the phase 3 flash (fluorescent light activated synthetic hypericin) study, presented confirmatory data at the society for investigative dermatology (sid) virtual meeting, held may 3-8, 2021.
SNGX Ratings Summary
SNGX Quant Ranking